PRNews

Early Treatment Is Revolutionizing Outcome Of Burn Scars

Lasers are improving severe scars and pain in Military personnel and burn victims

BURLINGTON, Massachusetts, July 25, 2017 /PRNewswire/ — Early treatment of burn scars with lasers is revolutionizing the outcome of many burn and trauma scar patients. In the past, doctors were taught to wait at least a year before treating burn and trauma scars, but according to Jill Waibel, MD, “That’s really counterintuitive, because the scars get worse. These patients can have horrific, disfiguring, painful contracture scars that form and a lot of our patients are children. We’ve seen that when you go in early, they need less surgery and less laser treatment.”

Laser devices, such as the Lutronic eCO2 laser, originally designed to treat wrinkles and acne scars, are found to have the capability to also improve disfiguring burn scars and other scars, as well as significantly reduce pain in these patients. Jill S. Waibel, MD, world renown Dermatologist, recently completed a clinical trial with Lutronic Aesthetics, proving early scar treatment with lasers is successful and she has been using this approach in practice and with her work on military personnel with battle scars for the last four to five years. Dr. Waibel has also helped many children and people of all ages with burn scars, surgery scars and scars of all types and shares her knowledge with other physicians around the globe.

“I believe we were the first to treat a burn survivor with fractional ablative CO2 in 2011. This is the first randomized control study in severe trauma patients to show early intervention with the Lutronic eCO2 prevents scarring when used within the first 3 months after burn injury. This information could potentially help patients live a better quality of life.” Jill S. Waibel, MD

Dr. Waibel will be discussing the topic “Early Intervention – New Paradigm in Treatment of Burn Scars” in a live Webinar on July 27th. For more information or to register, please visit www.usa.lutronic.com.

About Lutronic 
Lutronic, a leading innovator in advanced aesthetic and medical laser technology, was established over 19 years ago to bring state-of-the-art innovative, yet affordable devices to the worldwide aesthetic community.  All systems optimize outcomes for a wide variety of conditions and treatments including melasma, burn scars, tattoo removal, vascular lesions, hair removal, wrinkle reduction, rejuvenation, body/face contouring, chronic pain, healing and more.

Devoting more than 20% of revenue to R&D, Lutronic holds more than 200 current and pending patents worldwide. With more than 270 employees worldwide, Lutronic has offices in the US, Korea, China and Japan, a world-wide network of distributors and a focused R&D center in Korea.

For more information about LUTRONIC, visit: www.lutronic.com

If you would like more information about this topic, please contact Rachel Deschamps at 603-560-5103 or email at rdeschamps@lutronic.com.

Contact

Rachel Deschamps

Cell

603-560-5103

Email

rdeschamps@lutronic.com

Website

www.usa.lutronic.com
PRNews

U.S. FDA Determines Celliant (R) Responsive Textile Products Meet Criteria as Medical Devices and General Wellness Products

– Hologenix, LLC’s technology is first of its kind to secure joint FDA designations 

– Celliant-engineered products clinically proven to promote increased localized blood flow

– FDA determination to usher in new era of performance fabrics, responsive textiles

LOS ANGELES, July 25, 2017 /PRNewswire/ — Hologenix, LLC, maker of Celliant, the world’s most advanced, clinically tested responsive textile technology, announced today that the U.S. Food and Drug Administration (FDA) has determined Celliant products are medical devices and general wellness products, as defined in Section 201(h) of the Federal Food, Drug and, Cosmetic Act. According to the FDA, Celliant products were determined to be medical devices because they temporarily promote increased local blood flow at the site of application in healthy individuals.


PureCare Elements: Lumen® Premium Celliant® Sheet Set: The first linen collection that uses Celliant to increase comfort and promote faster recovery while you sleep.

SIMA award winner, Xcel Infinity Comp TDC Full Suit with Celliant: Uses Celliant to create the warmest wetsuit lining so you can surf longer and recover faster.

ISPO award winner, Tecnica Mach 1 Pro Women Ski Boot: A ski boot made for women by women that uses Celliant and Lambswool Heat from Imbotex in its lining to address women’s specific needs for warmth, comfort and performance on and off the slope. Release date: Fall 2017

Salewa Puez TirolWool Celliant Half Zip Jacket: Bends TirolWool, naturally warm, breathable and hydrophobic insulation from Imbotex, with Celliant to keep outdoor enthusiasts energized and warm all day long. Release date: Fall 2017

“Celliant-engineered products are the first of their kind that the FDA has designated as medical devices,” said Seth Casden, Hologenix CEO. “Our technology can be used in everyday products — t-shirts, clothing, bedding, even airplane seats — to create an increase in local blood flow thereby increasing energy, boosting performance and speeding muscle recovery.”

“We believe that Celliant is a truly disruptive technology that has transformational applications for textiles,” Casden said. “We’re currently evaluating additional applications of Celliant in the healthcare space, where, for example, people who suffer from diabetes might benefit from increased blood flow to body tissue.”

Celliant-engineered products harness and recycle the natural heat emitted by human beings to boost performance and rebuild and recharge the human body after physical activity and while you sleep. Celliant is made of a patented blend of thermo-reactive minerals infused into the core of fiber used to create all types of textiles and fabrics so it does not wash or wear out. Products made with Celliant fabric absorb and convert body heat into infrared energy (IR) that is recycled back into skin and tissue in a safe, natural way. IR is a vasodilator, increasing blood flow to tissue and muscles throughout the body, which delivers vital nutrients and oxygen to the cells. The effect is clinically proven to help the body:

  • increase energy, endurance, stamina and performance,
  • recover faster from physical activity,
  • promote restful sleep and increased comfort.

Celliant is used in a diverse range of textiles and applications – apparel, bedding, wetsuits and veterinary products, including:

  • SIMA award winner, Xcel Infinity Comp TDC Full Suit with Celliant which uses Celliant to create the warmest wetsuit lining so you can surf longer and recover faster;
  • Salewa Puez TirolWool Celliant Half Zip Jacket that blends TirolWool, naturally warm, breathable and hydrophobic insulation from Imbotex, with Celliant to keep outdoor enthusiasts energized and warm all day long. Release date: Fall 2017;
  • ISPO award winner, Tecnica Mach 1 Pro Women Ski Boot, a ski boot made for women by women that uses Celliant and Lambswool Heat from Imbotex in its lining to address women’s specific needs for warmth, comfort and performance on and off the slope. Release date: Fall 2017;
  • PureCare Elements: Lumen® Premium Celliant® Sheet Set, the first linen collection that uses Celliant to increase comfort and promote faster recovery while you sleep.

“Science has shown that infrared energy increases blood flow, improves muscle recovery and reduces long-term pain,” said Dr. Michael R Hamblin, principal investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital. “The FDA’s determination of Celliant products as medical devices and general wellness products will likely spur interest in infrared technologies and further development of garments and wraps that can positively impact people’s well-being.”

Celliant has been extensively researched, developed and clinically tested for both durability and effectiveness. Prominent institutions have conducted nine clinical trials to evaluate Celliant’s performance including University of California Irvine, University of Calgary, UCI Long Beach Veterans Affairs Medical Center, Texas A&M University, Loyola University Chicago and Exponent. Celliant technology has been shown to increase tissue oxygen levels by eight percent at the site of applicationi. Click here for NIH independent study on the benefits of IR on recovery.

About Celliant®
Celliant is a revolutionary, patented technology that harnesses and recycles the body’s natural energy through the medium of fibers. Celliant’s applied science utilizes a blend of minerals and proprietary ingredients that are embedded into the core of the fiber. Use of products containing this technology has been clinically proven to enhance tissue oxygen levels, improve athletic performance, sleep quality, health and wellness. Fibers, yarns and fabrics with Celliant technology can be found in some of the world’s most recognized name brands. For more information, visit www.celliant.com.  

About Hologenix, LLC
Founded in 2002, Hologenix, LLC, maker of Celliant technology, is committed to creating, developing and bringing to market products that enhance people’s lives through new materials. They strive to deliver the future of healthy innovation through a variety of consumer categories. In addition to the United States, Celliant is designated as a Class I medical device in Canada, European Union, Australia and New Zealand. The Company continues to explore new territories and is currently running FDA-focused, clinical trials to expand into the medical product arena.

i Dr. Ian Gordon – University of CA, Irvine, Effect of Garment with 42% Celliant Fiber on TCP02 Levels and Grip Strength in Healthy Subjects. 2010

Contact: Julia Moore, +1-212-445-8160, Julia.Moore@webershandwick.com

Photo – http://mma.prnewswire.com/media/538683/PureCare_Sheets.jpg
Photo – http://mma.prnewswire.com/media/538684/Xcel_Infinity_Comp_Full_Suit.jpg
Photo – http://mma.prnewswire.com/media/538685/Tecnica_Mach_1_Pro_Women_Ski_Boot.jpg
Photo – http://mma.prnewswire.com/media/538686/Salewa_Puez_TirolWool_Celliant_Half_Zip_Jacket.jpg
Logo – http://mma.prnewswire.com/media/538687/Celliant_Logo.jpg 

PRNews

Healthy Flight Recipe at 30,000 feet from Dr. Mehmet Oz with Turkish Airlines’ Fly Good Feel Good Project

“The Dr. Oz Show” Producer Led the Way by Hosting a Surprise In-Flight Show on Healthy Eating and Lifestyle with Passengers of Flight TK1 from Istanbul to New York

ISTANBUL, July 25, 2017 /PRNewswire/ — Turkish Airlines is collaborating with Dr. Mehmet Oz, the producer and host of world-renowned “The Dr. Oz Show”, on its “Fly Good Feel Good” project, aiming to provide an even more comfortable and healthy travel experience to its passengers. Dr. Oz gives advice to the passengers of Turkish Airlines, the airline flying to more countries than any other airline in the world, on healthy eating and exercises.

The collaboration between Turkish Airlines, Turkey’s National Flag Carrier airline, and Dr. Oz is part of “Fly Good Feel Good” project, which was created to improve the brand experience Turkish Airlines provides to its passengers. The project features short videos with expert advice presented on the Turkish Airlines official website, social media accounts and in-flight entertainment systems, and printed papers.

With help from Turkish Airlines pilots, cabin crew and the Flying Chef of flight TK01 from Istanbul to New York on July 23, Dr. Oz surprised passengers before filming content for his daytime show and the “Fly Good Feel Good” project. As part of this special flight experience, Dr. Oz entertained some 300 passengers of this special flight with health-inspiring gifts and messages over the in-flight entertainment system.

“Making our passengers’ flight experience more comfortable and enjoyable by continuously improving our brand experience is one of our top priorities.” Mr. M. Ilker Ayci, Chairman of the Board and the Executive Committee of Turkish Airlines, said. “How a person feels is just as important as our award-winning service quality. Dr. Oz will create a special atmosphere onboard where our passengers will better feel the privilege of flying with Turkish Airlines.”

“Turkish Airlines is world-renowned and awarded for its high quality service and perfect catering. “Fly Good Feel Good” is, too, an impressive project mindful of the health and wellness dimension of airline travels. I believe that this project is a great example of the attention put on the passengers by bringing the brand experience of Turkish Airlines to a higher level.”

The collaboration with Dr. Oz is the next phase of the Fly Good Feel Good project, which addresses all actions to be taken before, during and after flight in order to make passengers have a good flight in all aspects based on a good flight experience.

As part of the “Fly Good Feel Good” project, Turkish Airlines has also initiated the volunteer-based “Flying Doctor” practice for when an on-board doctor is needed, which enables physicians who register with the program and gain extra miles on their flights.

In the latter phases of the project, Turkish Airlines will continue to take passenger satisfaction to even higher levels and continue to advice its passengers about healthy living.

Please visit #flygoodfeelgood for The Dr. Oz Show that took place in midair and http://www.flygoodfeelgood.com/en/ for detailed information on Fly Good Feel Good.

Turkish Airlines, Inc.
Media Relations

Download more images and video here: bit.ly/2uZNUPp

Turkish Airlines Inc.
Office of Media Relations
General Management Building
34149, Yesilköy-Istanbul
Tel:  +90 (212) 463 63 63 – 11153 / 11173
Fax: +90 (212) 465 20 78
press@thy.com 


Dr. Mehmet Oz aboard TK1 from Istanbul to New York

Video – http://mma.prnewswire.com/media/538548/Turkish_Airlines_Flight_Video.mp4 
Photo – http://mma.prnewswire.com/media/538546/Turkish_Airlines_Dr_Mehmet_Oz.jpg 
Photo – http://mma.prnewswire.com/media/538594/TurkishAirlinesLogo.jpg 

PRNews

Frost & Sullivan Awards Gala Draws in Top Industry Leaders for Prestigious Recognition

Outstanding company achievements recognized at Frost & Sullivan Awards Ceremony

MOUNTAIN VIEW, California, July 20, 2017 /PRNewswire/ — Frost & Sullivan honored recipients at its Excellence in Best Practices Awards Gala held July 19th in Nashville, TN at the Loews Vanderbilt Hotel.

The Best Practices Awards are presented each year to companies that are predicted to encourage significant growth in their industries, have identified emerging trends before they became the standard in the marketplace, and have created advanced technologies that will catalyze and transform industries in the near future.

“Frost & Sullivan’s Awards program has now been recognizing companies for more than fifteen years,” said Jeff Frigstad, Global Sr. Vice President, Best Practices, Frost & Sullivan. “These Awards come from the rigor used by our talented team of 2,000 thought leaders from over 50 global offices working with over 200,000 clients, to locate the best.”

Awarded companies included:

ACI Worldwide – 2017 United States Digital Payments Customer Value Leadership Award

Aprima Medical Software – 2017 United States Ambulatory Revenue Cycle Management Product Leadership Award

AT&T – 2017 United States Business Metro Carrier Ethernet Services Market Leadership Award

AutoGravity Corporation – 2017 North American Digital Automotive Financing Entrepreneurial Company of the Year Award

bioMérieux – 2017 Global Automated Nucleic Acid Extraction New Product Innovation Award

Bio-Microbics, Inc. – 2017 North American Integrated Water Treatment Technology Leadership Award

Cisco Systems – 2017 Global Network Firewall Market Leadership Award

CliniOps – 2017 North American Digitalization of Clinical Trials Technology Leadership Award

CytoSorbents Corporation – 2017 Global Blood Purification Product Leadership Award

DataRPM – 2017 North American Cognitive Predictive Maintenance in Automotive Manufacturing Technology Leadership Award

Drivewyze, Inc. – 2017 North American Weigh Station Bypass Company of the Year Award

Ekahau – 2017 Global Wi-Fi Network Planning, Deployment, Verification & Troubleshooting Customer Value Leadership Award

FourKites, Inc. – 2017 North American Dynamic Supply Chain Tracking Solutions Entrepreneurial Company of the Year Award

Impinj – 2017 North American RFID Solutions in Healthcare Customer Value Leadership Award

INXPO, Inc. – 2017 Global Web Event Services Growth Excellence Leadership Award

IriTech, Inc. – 2017 North American Biometrics-as-a-Service New Product Innovation Award

MercuryGate International, Inc. – 2017 North American Cloud TMS for Retail Product Leadership Award

MobileIron – 2017 North American Enterprise Mobility Management Product Line Strategy Leadership Award

Omnify Software – 2017 North American PLM for the Mid-sized Medical Devices Customer Value Leadership Award 

Oracle – 2017 North American Health Data Warehousing Product Leadership Award

Pilgrim Quality Solutions, Inc. – 2017 North American Enterprise Quality Management Solution for Pharmaceutical Product Leadership Award

Proscia – 2017 Global Cloud-Based Digital Pathology Enabling Technology Leadership Award

Qualys, Inc. – 2017 Global Vulnerability Management Market Leadership Award

Sonus Networks – 2017 North American Enterprise Session Border Controller Company of the Year Award

Spectrum Enterprise – 2017 United States Business Carrier Ethernet Services Competitive Strategy Innovation and Leadership Award

Swissray International, Inc. – 2017 Global Magnetic Resonance Imaging Price/Performance Value Leadership Award

The Sente Group, Inc. – 2017 North American Test Resource Management Software Customer Value Leadership Award

TMEIC – 2016 Global PV Inverter Company of the Year Award

ToolsGroup – 2017 North American Supply Chain Management for Retail & Wholesale Technology Leadership Award

TruTag Technologies, Inc. – 2017 North American Product Authentication Technology Innovation Award

Unisys – 2017 North American Automated Encrypted Network Security Solution Customer Value Leadership Award

Virtual Hold Technology – 2017 North American Contact Center Software New Product Innovation Award

VirtualHealth – 2017 North American Population Health Management Product Leadership Award

Vodafone Group – 2017 European Cloud Communications and Contact Centers Company of the Year Award

Xerafy – 2017 Global RFID Surgical Instrument Tracking New Product Innovation Award

Yamaha Corporation – 2016 Global Tabletop Audio Conferencing Endpoint Growth Excellence Leadership Award

Yokogawa Electric Corporation – 2017 Global Automation Solutions and Services Customer Value Leadership Award

Zang, an Avaya Company – 2017 North American Communications Platforms as a Service New Product Innovation Award

Zendrive – 2017 North American User-Based Insurance Product Leadership Award

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices.

For further information about the Awards Gala, please contact a member of the Best Practices Team.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that could make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Estefany Ariza
P: 210.477.8469
F: 210.348.1003
E: estefany.ariza@frost.com

PRNews

Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry

I2E makes natural language processing-based text mining intuitive and interactive

SANTA CLARA, California, July 20, 2017 /PRNewswire/ — Based on its recent analysis of the Big Data text analytics market for the healthcare industry, Frost & Sullivan recognizes Linguamatics with the 2017 Global Frost & Sullivan Award for Enabling Technology Leadership. Linguamatics stands out in the natural language processing (NLP) market for its technology expertise and commitment to delivering exceptional value to clients in the US healthcare industry. The highly flexible and scalable Linguamatics Health platform, powered by I2E, is helping healthcare providers and payers to transition to value-based care.

Within the last year, Linguamatics introduced its fifth iteration of I2E, which includes cutting-edge capabilities such as the normalization of concepts and relationships for quick and comprehensive data retrieval regardless of format; advanced range research; and an extraction and search query language (EASL). The EASL can be generated external to the platform to support custom interfaces, queries in a human-readable format, and superior workflow automation.

“Linguamatics I2E is designed to identify the various nuances of language, such as understanding the difference between ‘history of cancer’ and ‘family history of cancer.’ Further, the I2E 5.0 release identifies precise numerical information in context, like the tumor size and medication dosages,” said Frost & Sullivan Transformational Health Principal Industry Analyst Victor Camlek. “The platform can cluster and categorize multiple concepts based on plugged-in terminologies, thesauri, or ontologies. It finds the perfect balance between linguistic context and medical text negation, ensuring that a search of ‘no evidence of pneumonia’ does not result in a diagnosis of ‘pneumonia.'”

Linguamatics also recently introduced the I2E Asynchronous Messaging Pipeline (I2E AMP) to help healthcare professionals find critical clinical insights faster. With I2E AMP, the Linguamatics platform can automate the Big Data mining of streams of data across multiple servers, providing organizations with scalability as their NLP text mining requirements grow.

Linguamatics I2E is highly flexible and can mine data from many types of data sources, including electronic health records (EHRs), clinical trial and news feeds, medical literature, social media, and lifestyle data. The platform can be deployed as an in-house enterprise system, as a value-add enterprise search capability, or as a software-as-a-service (SaaS) on the cloud. In addition to real-time processing of Big Data, I2E also provides powerful linguistic and data exploration techniques that allow patterns of language to be explored and new ontologies to be boot-strapped from basic principles, such as representations of social determinants of health within discharge summaries.

Linguamatics collaborates closely with health systems to incorporate functionalities that reduce physicians’ manual efforts, while providing real-time point-of-care clinical decision support. The platform provides varied inquiry options, ranging from entity extraction to complete linguistic analysis. An entire patient profile can be built using the right combination of smaller queries, and intelligent searches can lead to the creation of smart queries that can be deployed for a larger user base.

“With its flexibility, transparency, and speed, the I2E platform gives users complete control so they can refine searches on-the-go,” noted Camlek. “Query creation is completely configurable, ensuring that clinical users or business users do not need to be NLP or technical experts. Additionally, for advanced searches, an intuitive drag-and-drop graphical interface helps users view and manage the required queries.”

Overall, for developing a technology that a wide range of companies in the healthcare industry can adopt to create better solutions for their customers, Frost & Sullivan is pleased to present Linguamatics with the 2017 Global Frost & Sullivan Award for Enabling Technology Leadership.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Linguamatics

Linguamatics transforms unstructured big data into big insights to advance human health and wellbeing. A world leader in deploying innovative natural language processing (NLP)-based text mining for high-value knowledge discovery and decision support, Linguamatics’ solutions are used by top commercial, academic and government organizations, including 18 of the top 20 global pharmaceutical companies, the US Food and Drug Administration (FDA) and US National Cancer Institute, Cancer Research UK, and leading US healthcare organizations.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

PRNews

Frost & Sullivan Lauds eClinicalWorks for Providing Best-in-class RCM Services to a Wide Range of Independent and Hospital-acquired Physician Practices

eClinicalWorks’ large team of skilled professionals and ecosystem partners ensures hassle-free operation of its RCM services

SANTA CLARA, Calif., July 19, 2017 /PRNewswire/ — Based on its recent analysis of the ambulatory revenue cycle management (RCM) market, Frost & Sullivan recognizes eClinicalWorks with the 2017 North American Frost & Sullivan Award for Customer Value Leadership. eClinicalWorks pioneered a cost-effective, streamlined approach to billing in the ambulatory RCM market with its integrated cloud-based solution. For 2.9% of the monthly collection, it offers physicians comprehensive billing solutions, and prevents existing customers of electronic health record (EHR)/patient heath management/hospital management/patient engagement/cloud services from outsourcing billing services to external vendors. eClinicalWorks’ solutions integrate seamlessly with other proprietary health IT applications, allowing key provider executives to measure and monitor billing performance through unified dashboard reporting, powered by predictive financial analytics.


Frost & Sullivan recognizes eClinicalWorks with the 2017 North American Customer Value Leadership Award.

Click here to read the full Award Write Up – http://bit.ly/2uAagpJ

eClinicalWorks’ cloud-based solution boasts an uptime of 99.9% and has achieved a 98% first-pass acceptance for practice claims. It incorporates both the national rules engine, as well as the company’s own rules engine, so that reimbursements are evaluated efficiently and physician practices become eligible for various payer and state incentives.

“The company has assembled progressive technology modules that digitize the entire billing ecosystem end-to-end. It performs patient insurance eligibility assessment in real time, manages denials, investigates reasons for underpayments, periodically updates database rules, and automates the process of claims adjudication,” said Frost & Sullivan Industry Analyst Koustav Chatterjee. “eClinicalWorks’ built in RCM console also allows customers to monitor claims volumes at an enterprise level.”

Significantly, RCM operations largely require professionals with expertise in optimizing billing and collection for the cost incurred during patient care. eClinicalWorks’ highly skilled billing experts and ecosystem-level partners that have high-value technical capabilities in coding compliance, coding validation, bank reconciliation, and collection ensure that customers do not have to seek third-party help.

“eClinicalWorks is also widely popular among physician practices because of its round-the-clock and customer-friendly service. Dedicated account management teams carefully assess customer queries raised for patient registration, claims processing, and final collection, and make sure that payer reimbursement or self-payments made by patients are delivered directly to providers,” noted Chatterjee. “Technology, coupled with custom service capabilities, are helping eClinicalWorks garner optimum success in this service line.”

eClinicalWorks is a proven leader in the US ambulatory EHR market with an estimated market share of 10.2%, second only to Epic with 11.2%. The company offers advanced health IT solutions to almost 125,000 physicians and nurse practitioners, and its various service lines are used by more than 850,000 providers across all 50 US states, and globally in 20 countries.

For its ability to aid physicians with all their RCM needs and comply with regulations, Frost & Sullivan is pleased to present eClinicalWorks with the 2017 North American Frost & Sullivan Award for Customer Value Leadership.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company’s inordinate focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention, and, ultimately, customer base expansion.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About eClinicalWorks

eClinicalWorks® is a privately held leader in healthcare IT solutions. With more than 125,000 physicians and nurse practitioners using its solutions, customers include ACOs, physician practices, hospitals, community health centers, departments of health, and convenient care clinics. During the past eight years, 16 eClinicalWorks customers have received the prestigious HIMSS Davies Award, honoring excellence in electronic health record implementation. The company is second largest in the country for e-prescribing. Based in Westborough, Mass., eClinicalWorks has additional offices in Austin, New York City, Chicago, California, Georgia, London, India, and Dubai. For more information, please visit www.eclinicalworks.com, Facebook, Twitter or call 866-888-6929.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Samantha Park
P: +1 210.247.2426
F: +1 210.348.1003
E: samantha.park@frost.com

Photo – https://mma.prnewswire.com/media/537159/Frost_Sullivan_eClinicalWorks_Award.jpg

PRNews

Frost & Sullivan Commends Oracle’s Expertly Engineered Unified Healthcare Analytics Platform, Oracle Healthcare Foundation

-Oracle Healthcare Foundation is the ideal tool to support the healthcare industry’s current and future data integration and data quality challenges

SANTA CLARA, California, July 19, 2017 /PRNewswire/ — Based on its recent analysis of the health data warehousing market, Frost & Sullivan recognizes Oracle Health Sciences with the 2017 North American Frost & Sullivan Award for Product Leadership. Stepping out of its IT industry stronghold, Oracle has engineered a highly organized version of its data warehouse, Oracle Healthcare Foundation (OHF), for the special needs of the healthcare industry. The solution’s unified analytics platform processes traditional clinical and claims data, financial and operational data and supply chain, human resources, administrative, and operational functions.


Oracle

Oracle Healthcare Foundation is a feature-rich analytics platform that supports more than 35 subject areas relevant to health data analytics, giving healthcare providers more granular data regarding the requirements of individuals and populations. They can use this data to effect process changes and quality improvement initiatives as well as leverage its out-of–the-box self-service analytics tools to build customized analytics solutions.

“The solution’s comprehensive, scalable, end-to-end platform enables data acquisition, validation, integration, warehousing, and analytics. It encompasses all data types and sources, delivering clinical, financial, administrative, and omics modules,” said Frost & Sullivan Principal Analyst for Digital Health Nancy Fabozzi. “It facilitates rigorous data integration, data governance, and data quality, driving greater engagement and adoption by operations, financial management, and clinical care delivery teams across the healthcare enterprise.”

Oracle Healthcare Foundation can be deployed as a complete or modular solution and as an on-premise, cloud, or hybrid solution, all depending on the customer’s unique needs.

“We strive to provide our customers with a range of capabilities that deliver a solid, stable and reliable core data foundation that will enable them to propel their healthcare businesses forward and scale to their future data analytics needs,” said Jonathan Sheldon, Global Vice President, Oracle Health Sciences.

Oracle understands that scientific advancement is resulting in new complex data types such as genome sequencing that need to be incorporated into the data warehouse and made available for clinical decision making. For this to happen successfully, the data warehouse must have the capacity to expand in a way that keeps the data footprint consistent and not leave any gaps. Oracle has made optimum use of its technology expertise and resources to reduce the amount of time and effort needed to set up and maintain a robust data warehouse.

“A stable data warehouse can reduce the effort required to tie together all of the customer’s data resources, normalize data, map new pieces of data or data types, and so on,” noted Fabozzi. “With Oracle Healthcare Foundation, all of this takes place in one stable solution, automated so that relatively few people are required to maintain it once it is set up. In doing so, Oracle allows its customers to shift essential human resources to higher value analytics activities instead of engaging them in connecting a data feed or finding an appropriate analytics application.”

Oracle strives for a very collaborative relationship with its customers and together, they drive the product roadmap. This partnership ensures that as Oracle builds out the data model and requirements, customers stay informed and the solution always meets their needs.

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Oracle
The Oracle Cloud delivers hundreds of SaaS applications and enterprise-class PaaS and IaaS services to customers in more than 195 countries and territories while processing 55 billion transactions a day. For more information about Oracle (NYSE:ORCL), please visit us at oracle.com.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:
Estefany Ariza
P: 210.477.8469
F: 210.348.1003
E: estefany.ariza@frost.com

PRNews

MyDx Files Complaint Against Former Chief Operating Officer, Protects Unique AeroDx Diagnostic Platform and Addresses Toxic Financier’s Unauthorized Conversion

SAN DIEGO, July 18, 2017 /PRNewswire/ — MyDx, Inc. (OTCQB:MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer initially designed for cannabis professionals and retail consumers to measure the chemicals in cannabis and track their feedback on how each sample is impacting their physiology, today announced that all previously reported variable toxic debts have been satisfied through the unauthorized conversion of the Crown Bridge note and has also filed a lawsuit against its former COO and other defendants who have attempted to create a competitive advantage with its anticipated product launch of its air quality sensor: AeroDx®.


MyDx 2.0 Analyzer with CannaDx and AeroDx Sensor Compatibility

Lawsuit to Protect Unique AeroDx Diagnostic Platform
On July 14, 2017, the Company and its Chief Executive Officer, Daniel Yazbeck, filed a complaint in Superior Court of California against a series of Defendants who have allegedly engaged in unfair business practices, made false statements about the Company, its products, and Mr. Yazbeck at investor events and on online investor platforms.  There can be no assurance about the results or on the outcome of the lawsuit, however, the company took aggressive steps it felt were necessary to protect its business and its shareholders.

AeroDx®: MyDx’s Air Quality Sensor
AeroDx Sensors are the first of three anticipated versatile sensors to be launched into the market and represents the first versatile sensor to be used with the new release of the MyDx 2.0 Analyzer launched in May of this year.  AeroDx is expected to measure key air quality parameters for cannabis and non-cannabis consumers, to be interchanged seamlessly with the CannaDx Sensors. Once AeroDx Sensors are inserted into the MyDx Device, the device becomes an air quality tester with the ability to detect Volatile Organic Compounds (VOC’s) such as Formaldehyde, Butane, Toluene, Methane, Benzene and other harmful chemicals, such as Carbon Dioxide, present in the air. It can also monitor temperature and humidity, which can aid in preventing mold and germ growth. The company is also in the process of customizing the sensor in order to ensure air quality and control in cannabis growth facilities as well offer a test for residual solvents in cannabis oils.

Addressing Remaining Toxic Variable Convertible Debt on Balance Sheet
 On April 30, 2017, the Company sent a payoff demand to Crown Bridge Partners, LLC as required under the terms of the loan Agreement.  The Company agreed to repay, in full, the remaining variable toxic convertible note on its balance sheet prior to the prepayment deadline. Crown Bridge acknowledged the request and despite the Company and its counsel’s repeated payoff request, on July 3, 2017, Crown converted $36,749.04 (the entire amount due pursuant to the Note, including penalties and interest) into 14,699,616 shares of the Company’s common stock. In light of the Company’s notification and Crown Bridge’s acknowledgment required under the terms of the loan Agreements, Crown Bridge executed the conversion and the Company alleges it breached the terms of the Note. The Company will continue to evaluate its rights and determine the best course of action to advance the interests of its shareholders.

As of July 17, 2017, all previously reported variable rate toxic financing has been fully paid off.

About MyDx, Inc.
 MyDx, Inc. (OTCQB: MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx AquaDx®, OrganaDx(TM) and CannaDx(TM) sensors are now commercialized, and the AeroDx® application is next in line. All sensors will be compatible with a MyDx App that empowers consumers to live a healthier life by revealing the chemical composition of what they eat, drink and inhale. For more information, please visit www.mydxlife.com.

Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov. MyDx is not considered a medical device.  Consumers should be advised that any claims regarding the medical benefits of cannabis are still under research and until approved by the FDA or any other relevant international regulatory body, are considered anecdotal in nature. 

Investor Contact:
MyDx Shareholder Communications
800.814.4550 ext. 4
ir@cdxlife.com

Photo – http://mma.prnewswire.com/media/536158/MyDx_Inc_Analyzer_with_CannaDx.jpg 

Source: MyDx, Inc.

PRNews

CROMSOURCE Celebrates Its 20th Anniversary

VERONA, Italy, July 18, 2017 /PRNewswire/ —

CROMSOURCE marks its twentieth anniversary of providing high quality clinical research services and exceptional customer support to our global pharmaceutical, biotechnology, and medical device clients.

For the last twenty years, CROMSOURCE has been a valued partner to hundreds of global clients, having provided services for more than 3000 clinical trials across a number of important areas. Much of the work which we have performed has led to the approval and marketing of life-changing and life-saving medical products across the globe.

“CROMSOURCE’s twentieth anniversary is an exciting milestone for our company! When I started this adventure, one goal was that CROMSOURCE would become an international provider serving customers all over the world. It is with great pride that today we can say that we have accomplished that ambition,” said Dr. Oriana Zerbini, founder and CEO of CROMSOURCE.

“Moreover, CROMSOURCE could only have achieved such success with the involvement of its employees and clients. We are proud of having the confidence of our clients and being a trusted partner for their product development programs. And, of course, our employees are the heart of our growth and success. Their diligence, motivation, passion, and unwavering dedication have all been a source of inspiration for reaching this important milestone,” continued Dr. Zerbini.

“Looking toward the future, we recognize the need to evolve as the world, and our industry, continues to experience rapid change. Thanks to our talented professionals and flexible approach to performing clinical research services, we are uniquely positioned to be the ideal partner for the most complex and challenging development programs. We also believe the best for CROMSOURCE and our clients and employees is yet to come based on our existing and growing pipeline of opportunities ranging from early phase through post-marketing studies across an important array of therapeutic areas, medical devices, and rare diseases,” said Dr. Troy McCall, Chief Operating Officer stated.

About CROMSOURCE     

CROMSOURCE is an ISO-certified, international provider of outsourced services to the pharmaceutical, biotechnology, and medical device industries, specialized in clinical development and staffing solutions. We  offer a flexible approach to ensure our clients’ unique needs are supported. CROMSOURCE is unparalleled in offering an end-to-end guarantee covering trial timelines, enrollment, and price.  CROMSOURCE operates offices across all regions of Europe and North America. For more information, visit http://www.cromsource.com.

Contact Info
Margherita Mosconi
margherita.mosconi@cromsource.com
+39-045-82-22-811

PRNews

People’s Republic of China Approves Proliant Biologicals for the Importation of New Zealand BSA

ANKENY, Iowa and FEILDING, New Zealand, July 17, 2017 /PRNewswire/ — Following a recent Chinese decision, centered around New Zealand Origin Bovine Material, Proliant Biologicals is now eligible to ship its New Zealand Bovine Serum Albumin (BSA) into the country.  The change comes after months of restricting the importation of any bovine blood products of New Zealand origin into the country.

With the Chinese border now open to Proliant New Zealand and its BSA, it is Proliant’s goal to help support the continued growth of the Chinese Diagnostic, Life Science, Vaccine, and Cell Culture markets, among others.  As the population continues to increase and as more and more Chinese gain access to healthcare, the development of these markets is as vital as ever. 

Proliant Biologicals, and its New Zealand BSA manufacturing facility, is in a unique position to help service the expanding Chinese Life Science industries.  The facility, located in Feilding, is registered with the MPI and is Traceability Certified by the International Serum Industry Association (ISIA).  With dual manufacturing facilities (New Zealand and US), Proliant is the only BSA manufacturer in the world who holds ISIA traceability certificates.

For more information pertaining to Proliant’s New Zealand BSA and its facility, please utilize the following link: http://www.proliantbiologicals.com

Grade

Material Origin

Part Number

Standard Grade pH 7.0

New Zealand

69100

Reagent Grade (Fatty Acid-Free)

New Zealand

Coming Soon

About Proliant Biologicals, Inc.

Proliant is the world’s premier manufacturer of animal extracts and consistent, reliable, traceable Bovine Serum Albumin (Fraction V).  All Proliant bovine albumins are made from Proliant-collected USDA/MPI Edible grade Plasma; and are protease-free, IgG-free, low endotoxin & bioburden with outstanding solubility/filterability characteristics.

Proliant Biologicals is part of the LGI group of companies, premier manufacturer of protein ingredients for food, health, nutrition and biologicals.  Proliant along with American Protein Corporation, BHJ Corporation and Boyer Valley Corporation are privately held companies of the Lauridsen Group Incorporated.

Source: Proliant Biologicals, Inc.

Exit mobile version